Currently, three clinical trials are evaluating the efficacy of tocilizumab, an anti-IL-6 mAb, in combination with atezolizumab in locally advanced or metastatic NSCLC (NCT04691817), in combination with ipilimumab and nivolumab in melanoma, NSCLC, and urothelial cancer (NCT04940299), and in a multi-immunotherapy two-phased therapy in combination with chemotherapy or PD-1 inhibitors in metastatic NSCLC subjects (NCT03337698). Here, IL6 is linked to non-small cell lung carcinoma.